Steroids, IVIG, and romiplostim for severe ITP
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a combination of three treatments—steroids, IVIG, and romiplostim (Nplate)—for adults with severe, newly diagnosed ITP that hasn't responded well to standard therapy. The goal is to see if this triple therapy can quickly raise platelet counts and stop bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your platelet count is very low (below 10) and you have active bleeding or a bleeding score of 5 or higher.
- You have not had your spleen removed and have had at least one standard ITP treatment (like steroids or IVIG) in the past.
- You have never taken the drug romiplostim (Nplate).
- You do not have other blood disorders, a history of blood clots, or a serious infection, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
This trial tests if adding romiplostim (a drug that helps make platelets) to standard steroid treatment works better than steroids alone for adults who have not been treated for ITP before. It is for people with low platelet counts and may help reduce bleeding.
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
This trial tests if eltrombopag, a medication that helps the body make more platelets, works as the first treatment for people newly diagnosed with immune thrombocytopenia (ITP, a condition where the immune system destroys platelets, causing bleeding problems). It may help raise your platelet count and reduce bleeding risk.
This trial tests a two-step approach for adults with severe ITP: first a growth factor injection (rhTPO), then a pill (eltrombopag). The goal is to see if this sequence works better than steroids alone to raise platelet counts safely.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.